Together, we can stop the spread.
- + Get your results at the doctor's office in less than 15 MINUTES +
Together, we can stop the spread.
- With Perfumarie's Innovation Lab, you can now have ongoing access to the top-rated proven COVID-19 rapid antibody test for your establishment.
Together, we can stop the spread.+ Get your results at the doctor's office in less than 15 MINUTES +
Together, we can stop the spread.With Perfumarie's Innovation Lab, you can now have ongoing access to the top-rated proven COVID-19 rapid antibody test for your establishment.
What is a rapid COVID test and how does it work?
Until now, the standard for COVID-19 testing has revolved around two main methods: molecular testing and antibody testing. The former involves the iconic nasal or throat swab sampling to check for the presence of the virus itself. This molecular testing technique is known as reverse transcription-polymerase chain reaction (RT-PCR). It detects viral genetic material from the sample.
Antibody testing involves checking for the presence of antibodies that one’s immune system develops in response to the virus. For this purpose, blood samples from a finger prick undergo analysis with a serology test.
However, both PCR and traditional serology tests require trained personnel and specific equipment to perform. Additionally, depending on the proximity of the testing lab, they can take hours or days to provide a result.
On the other hand, rapid COVID tests, as the name suggests, offer a quick diagnostic method to determine if someone is infected with SARS-CoV-2; as quickly as 15 minutes.
Introducing the First FDA-Authorized Fingerstick Whole Blood/Serum/Plasma COVID-19 Rapid Antibody Test
Intended to screen patients for COVID-19, this test is used to identify people who have been exposed to COVID-19 and if they have the potential to provide protection against further infections.
• COVID-19 Rapid Tests are an excellent tool to understand the prevalence of COVID-19 amongst a group of people.
• Antibody carriers can also donate their plasma as a potential treatment for seriously ill COVID-19 Patients.
• COVID-19 Antibodies have been found to last for at least 4 months.
• Blood tests have been found to be more reliable and better for tracking the spread of the disease in a region and for guiding decisions and returning to work or school.
• Combining RNA and Antibody tests can significantly raise the sensitivity for detecting COVID-19 in infected individuals.
• Type: Lateral Flow Assay • CE Certified
• Production Capacity: 20 Million tests/month
Get your results at the doctor's office in less than 15 MINUTES!
CLIA Waived. There is NO NEED to send samples to the lab.
Until today, serology test samples were generally only able to be evaluated in a central lab, which can be time consuming and use additional resources to transport samples and run the test. As more and more point-of-care serology tests are authorized, they will help conserve those resources and may help reduce processing time for other types ofCOVID-19 tests, as less time is spent on serology tests
FDA Commissioner Stephen M Hahn, M.D.
Authorizing point-of-care serology tests will enable more timely and convenient results for individuals who want to understand if they have previously been infected with the virus that causes COVID-19.
Mindy Yang. CEO & Founder of Perfumarie
Together, we can prevent and stop the spread. Rapid Antibody Tests can help identify healthcare providers, patients, and community populations who have potentially developed an immune response to the COVID-19.
Using this information, people with coronavirus antibodies can make informed decisions about returning to work and other activities.
Made in the USA, this is the first and only point-of-care FDA/EUA authorized antibody test on the market!
• Minimum Order: 500 Tests (25 boxes @ $20/box)
• Sensitivity 100%; Specificity 98.8%
Results in 15 minutes!
The Assure Ecotest is not a diagnostic test, it is a screening test that is not for home use, but it has been FDA (EUA) Authorized to be used as a point-of-care test at CLIA Waived patient care settings.*
This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b) (1) of the Act, 21 U.S.C. #360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
*The FDA has granted this test emergency use authorization in CLIA moderate- or high-complexity setting. Please refer to your local regulations.
This test is also authorized for use with fingerstick whole blood specimens only at the Point-of-Care (POC), i.e. in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.